Document Detail


An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
MedLine Citation:
PMID:  21970659     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: There are two new treatment options available for the treatment of adenocarcinoma histology non-small cell lung cancer (NSCLC) which offer improved benefit in terms of progression-free (PFS) and overall survival (OS) over chemotherapy. Both bevacizumab and pemetrexed when combined with chemotherapy significantly increase PFS and OS in patients with advanced NSCLC versus chemotherapy alone. The aim of this analysis was to compare the efficacy for patients with non-squamous adenocarcinoma NSCLC treated with bevacizumab, carboplatin and paclitaxel (BCP) to pemetrexed and cisplatin (PC) by using indirect comparison (ITC) methodology.
EXPERIMENTAL DESIGN: In the absence of head-to-head trials, ITC was performed on patients with adenocarcinoma histology non-squamous NSCLC to compare the relative benefit of first-line therapies BCP vs. PC by hazard ratios (HR). Subsequently, these HRs were used in a decision-analytic Markov model with a lifelong time horizon to extrapolate the long-term effectiveness of the two treatments.
RESULTS: ITC estimated HRs for the primary endpoints in the bevacizumab study E4599 showed that BCP treatment in non-squamous adenocarcinoma NSCLC patients resulted in a BCP HR of 0.82 versus PC. The long-term predictions from the Markov model yielded a mean survival of 1.48 years (95% CI 1.34, 1.62 years) (or 17.7 months) for BCP compared with 1.29 years (95% CI 1.16, 1.42 years) (or 15.4 months) for PC.
CONCLUSIONS: Based on our decision analysis, triplet BCP targeted therapy in patients with advanced non-squamous adenocarcinoma NSCLC compared with doublet PC chemotherapy results in improved expected values for overall long-term survival. Therefore, from the efficacy perspective, bevacizumab in combination with platinum-based chemotherapy can be considered as the targeted therapy of choice for patients with advanced non-squamous adenocarcinoma NSCLC.
Authors:
Mark J C Nuijten; Rick Aultman; Javier de Castro Carpeño; Alain Vergnenègre; Christos Chouaid; Stefan Walzer; Uwe Siebert
Related Documents :
21837669 - Impact of low estrogen/progesterone receptor expression on survival outcomes in breast ...
1399729 - The prognostic significance of race and survival from prostate cancer based on patients...
24259969 - Radiofrequency ablation of hepatocellular carcinoma sized > 3 and ≤ 5 cm: is ablative...
24112249 - Immunotherapy following relapse of acute leukaemia after t-cell-replete allogeneic peri...
14519629 - Phase ii study of 1alpha-hydroxyvitamin d(2) in the treatment of advanced androgen-inde...
1405649 - Skeletal metastasis from occult carcinoma.
23564469 - Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly pa...
23634289 - Evaluation of 5-year imatinib treatment of 458 patients with cp-cml in routine clinical...
16110019 - Multicenter, randomized phase ii trial of oral ci-1033 for previously treated advanced ...
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't     Date:  2011-10-04
Journal Detail:
Title:  Current medical research and opinion     Volume:  27     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-10-17     Completed Date:  2012-06-07     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  2193-201     Citation Subset:  IM    
Affiliation:
Ars Accessus Medica, Rotterdam, The Netherlands. marknuijten@planet.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy*,  mortality,  pathology
Antibodies, Monoclonal, Humanized / administration & dosage,  therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carboplatin / administration & dosage,  therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*,  mortality,  pathology
Cisplatin / administration & dosage,  therapeutic use
Disease-Free Survival
Glutamates / administration & dosage,  therapeutic use
Guanine / administration & dosage,  analogs & derivatives,  therapeutic use
Humans
Markov Chains
Paclitaxel / administration & dosage,  therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Glutamates; 04Q9AIZ7NO/pemetrexed; 15663-27-1/Cisplatin; 2S9ZZM9Q9V/bevacizumab; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin; 73-40-5/Guanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biofriendly bonding processes for nanoporous implantable SU-8 microcapsules for encapsulated cell th...
Next Document:  Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus ...